Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
MeaTech 3D Ltd. develops a three-dimensional bioprinter to deposit layers of differentiated stem cells, scaffolding, and cell nutrients. The company intends to license its production technology; provide associated products, such as cell lines, printheads, bioreactors, and incubators.
No reported earnings periods on file.
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $10,000.00 | — |
| Gross profit | — | — | — | -$12,000.00 | — |
| Operating income | — | -$17.1M | -$14.2M | -$8.5M | -$7.4M |
| Net income | -$21.9M | -$21.9M | -$16.9M | -$8.5M | -$11.2M |
| Diluted EPS | — | — | -$0.07 | -$0.02 | -$0.01 |
| Operating cash flow | -$14.4M | -$14.8M | -$12.7M | -$8.5M | -$6.7M |
| Free cash flow | -$16.2M | -$17.7M | -$13.0M | -$9.4M | -$6.9M |
| Gross margin | — | — | — | -120.0% | — |
| Operating margin | — | — | — | -84760.0% | — |
| Net margin | — | — | — | -85210.0% | — |
No quarterly data.
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-30 | Atia Oren Yosi· Vice President of Finance | Award | 15,000 | $0.00 | $0.00 | filing |
Latest 1 transaction.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.